The latest price target for CARISMA Therapeutics (NASDAQ:CARM) was reported by HC Wainwright & Co. on December 16, 2024. The analyst firm set a price target for $0.00 expecting CARM to fall to within 12 months (a possible -100.00% downside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for CARISMA Therapeutics (NASDAQ:CARM) was provided by HC Wainwright & Co., and CARISMA Therapeutics downgraded their neutral rating.

There is no last upgrade for CARISMA Therapeutics

The last downgrade for CARISMA Therapeutics Inc happened on December 16, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for CARISMA Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CARISMA Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CARISMA Therapeutics was filed on December 16, 2024 so you should expect the next rating to be made available sometime around December 16, 2025.

While ratings are subjective and will change, the latest CARISMA Therapeutics (CARM) rating was a downgraded with a price target of $0.00 to $0.00. The current price CARISMA Therapeutics (CARM) is trading at is $0.42, which is out of the analyst’s predicted range.